{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:46:36Z","timestamp":1649155596136},"reference-count":51,"publisher":"Walter de Gruyter GmbH","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with atrial fibrillation are at increased risk of having a cardioembolic stroke. The use of oral anticoagulation is now well established to prevent strokes in patients with atrial fibrillation and a CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc (congestive heart failure, hypertension, age \u226575 years [2 points], diabetes mellitus, prior stroke\/transient ischemic attack or thromboembolism [2 points], vascular disease, age 65 to 74 years, and sex category) score of greater than 1, beyond sex. However, the role of antiplatelet therapy, specifically aspirin in low-risk patients or as an alternative to oral anticoagulation, remains controversial. The most recent US guidelines conflict with the European guidelines, which do not recommend antiplatelet monotherapy for stroke prevention irrespective of stroke risk. The aim of this review is to summarize published studies that question the role of aspirin in preventing strokes associated with atrial fibrillation. Overall, aspirin is found to play a limited role in the prevention of stroke in patients with atrial fibrillation and is associated with a similar risk of hemorrhagic events compared with anticoagulants. The benefit of dual antiplatelet therapy as an alternative to oral anticoagulation requires further study.<\/jats:p>","DOI":"10.7556\/jaoa.2017.148","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T20:30:51Z","timestamp":1511814651000},"page":"761-771","source":"Crossref","is-referenced-by-count":3,"title":["Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation"],"prefix":"10.1515","volume":"117","author":[{"given":"Rohini","family":"Manaktala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"issue":"5","key":"2022022615401146647_j_jaoa.2017.148_ref_001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications","volume":"155","author":"Feinberg","year":"1995","journal-title":"Arch Intern Med"},{"issue":"11","key":"2022022615401146647_j_jaoa.2017.148_ref_002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1474-4422(07)70264-8","article-title":"Atrial fibrillation and stroke prevention","volume":"6","author":"Lip","year":"2007","journal-title":"Lancet Neurol"},{"issue":"4","key":"2022022615401146647_j_jaoa.2017.148_ref_003","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.recesp.2011.01.001","article-title":"Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments [in Spanish]","volume":"64","author":"Gersh","year":"2011","journal-title":"Rev Esp Cardiol"},{"issue":"16","key":"2022022615401146647_j_jaoa.2017.148_ref_004","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"2022022615401146647_j_jaoa.2017.148_ref_005","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.amjcard.2016.05.029","article-title":"Interatrial block to guide the thromboembolic prevention strategy: should it be the next step [letter]?","volume":"120","author":"Chhabra","year":"2017","journal-title":"Am J Cardiol"},{"issue":"19","key":"2022022615401146647_j_jaoa.2017.148_ref_006","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/heartjnl-2013-305303","article-title":"APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores","volume":"100","author":"Mitchell","year":"2014","journal-title":". Heart"},{"issue":"10","key":"2022022615401146647_j_jaoa.2017.148_ref_007","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jama.2017.1371","article-title":"Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation","volume":"317","author":"Xian","year":"2017","journal-title":"JAMA"},{"issue":"21","key":"2022022615401146647_j_jaoa.2017.148_ref_008","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published correction appears in J Am Coll Cardiol. 2014;64(21):2304-2307]","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2022022615401146647_j_jaoa.2017.148_ref_009","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2013.02.001","article-title":"Management of patients with atrial fibrillation (compilation of 2006 ACCF\/AHA\/ESC and 2011 ACCF\/AHA\/HRS recommendations): a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"Anderson","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2022022615401146647_j_jaoa.2017.148_ref_010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"1","key":"2022022615401146647_j_jaoa.2017.148_ref_011","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3810\/hp.2013.02.1012","article-title":"Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants [review]","volume":"41","author":"Guo","year":"1995","journal-title":"Hosp Pract (1995)"},{"issue":"38","key":"2022022615401146647_j_jaoa.2017.148_ref_012","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"2022022615401146647_j_jaoa.2017.148_ref_013","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/qjmed\/94.12.665","article-title":"Paroxysmal atrial fibrillation","volume":"94","author":"Lip","year":"2001","journal-title":"QJM"},{"issue":"9","key":"2022022615401146647_j_jaoa.2017.148_ref_014","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/CIRCRESAHA.114.303211","article-title":"The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms [review]","volume":"114","author":"Andrade","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"2022022615401146647_j_jaoa.2017.148_ref_015","doi-asserted-by":"publisher","DOI":"10.4172\/jhtd.1000108","article-title":"Role of antiplatelet therapies in preventing atherothrombosis [review]","volume":"1","author":"Khalil","year":"2013","journal-title":"J Hematol Thromb Dis"},{"issue":"20","key":"2022022615401146647_j_jaoa.2017.148_ref_016","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1161\/CIRCULATIONAHA.111.019893","article-title":"Atrial fibrillation pathophysiology: implications for management [review]","volume":"124","author":"Iwasaki","year":"2011","journal-title":"Circulation"},{"issue":"20","key":"2022022615401146647_j_jaoa.2017.148_ref_017","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"The ACTIVE Investigators","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2022022615401146647_j_jaoa.2017.148_ref_018","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3122\/jabfm.18.6.528","article-title":"Long-term therapy to prevent stroke","volume":"18","author":"Kirshner","year":"2005","journal-title":"J Am Board Fam Pract"},{"issue":"6","key":"2022022615401146647_j_jaoa.2017.148_ref_019","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions [review]","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"2022022615401146647_j_jaoa.2017.148_ref_020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/VHRM.S6104","article-title":"Modern role for clopidogrel in management of atrial fibrillation and stroke reduction","volume":"6","author":"Maegdefessel","year":"2010","journal-title":"Vasc Health Risk Manag"},{"issue":"3-4","key":"2022022615401146647_j_jaoa.2017.148_ref_021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/09537109876799","article-title":"Clopidogrel: a review of its mechanism of action","volume":"9","author":"Savi","year":"1998","journal-title":"Platelets"},{"issue":"1","key":"2022022615401146647_j_jaoa.2017.148_ref_022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: a review","volume":"16","author":"Harter","year":"2015","journal-title":"West J Emerg Med"},{"issue":"6","key":"2022022615401146647_j_jaoa.2017.148_ref_023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjmed.2006.07.045","article-title":"The safety of warfarin therapy in the nursing home setting","volume":"120","author":"Gurwitz","year":"2007","journal-title":"Am J Med"},{"issue":"1","key":"2022022615401146647_j_jaoa.2017.148_ref_024","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1161\/STROKEAHA.108.516344","article-title":"Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated","volume":"40","author":"Gladstone","year":"2009","journal-title":"Stroke"},{"key":"2022022615401146647_j_jaoa.2017.148_ref_025","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events [review]","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"2022022615401146647_j_jaoa.2017.148_ref_026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5603\/CJ.2012.0002","article-title":"ARISTOTLE RE-LYs on the ROCKET: what's new in stroke prevention in patients with atrial fibrillation [review]","volume":"19","author":"Tendera","year":"2012","journal-title":"Cardiol J"},{"issue":"22","key":"2022022615401146647_j_jaoa.2017.148_ref_027","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2022022615401146647_j_jaoa.2017.148_ref_028","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus wafarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2022022615401146647_j_jaoa.2017.148_ref_029","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus wafarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"2022022615401146647_j_jaoa.2017.148_ref_030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2022022615401146647_j_jaoa.2017.148_ref_031","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation [review]","volume":"8","author":"Lip","year":"2011","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2022022615401146647_j_jaoa.2017.148_ref_032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"2022022615401146647_j_jaoa.2017.148_ref_033","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"9431","key":"2022022615401146647_j_jaoa.2017.148_ref_034","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"2022022615401146647_j_jaoa.2017.148_ref_035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation study: final results","volume":"84","year":"1991","journal-title":"Circulation"},{"issue":"8899","key":"2022022615401146647_j_jaoa.2017.148_ref_036","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study","volume":"343","year":"1994","journal-title":"Lancet"},{"issue":"1 pt 1","key":"2022022615401146647_j_jaoa.2017.148_ref_037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-8703(99)70259-0","article-title":"LASAF Pilot Study Group. Alternate-day dosing of aspirin in atrial fibrillation","volume":"138","author":"Posada","year":"1999","journal-title":"Am Heart J"},{"issue":"2","key":"2022022615401146647_j_jaoa.2017.148_ref_038","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","article-title":"Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial","volume":"37","author":"Sato","year":"2006","journal-title":"Stroke"},{"issue":"8882","key":"2022022615401146647_j_jaoa.2017.148_ref_039","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"issue":"4","key":"2022022615401146647_j_jaoa.2017.148_ref_040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0197-2456(99)00010-0","article-title":"Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: the PATAF trial study design","volume":"20","author":"Hellemons","year":"1999","journal-title":"Control Clin Trials"},{"issue":"8631","key":"2022022615401146647_j_jaoa.2017.148_ref_041","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"issue":"12","key":"2022022615401146647_j_jaoa.2017.148_ref_042","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study","volume":"159","author":"Gull\u00f8v","year":"1999","journal-title":"Arch Intern Med"},{"issue":"9586","key":"2022022615401146647_j_jaoa.2017.148_ref_043","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"2022022615401146647_j_jaoa.2017.148_ref_044","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2022022615401146647_j_jaoa.2017.148_ref_045"},{"key":"2022022615401146647_j_jaoa.2017.148_ref_046","doi-asserted-by":"publisher","first-page":"168","DOI":"10.12688\/f1000research.7384.1","article-title":"Diagnosis, prognosis, and management of cryptogenic stroke","volume":"5","author":"Zhang","year":"2016","journal-title":"F1000Res"},{"issue":"6","key":"2022022615401146647_j_jaoa.2017.148_ref_047","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/01.STR.0000016922.22707.27","article-title":"Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?","volume":"33","author":"Hankey","year":"2002","journal-title":"Stroke"},{"issue":"26","key":"2022022615401146647_j_jaoa.2017.148_ref_048","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2022022615401146647_j_jaoa.2017.148_ref_049","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"issue":"1052","key":"2022022615401146647_j_jaoa.2017.148_ref_050","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/postgradmedj-2012-131386","article-title":"Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice","volume":"89","author":"Sabir","year":"2013","journal-title":"Postgrad Med J"},{"issue":"11","key":"2022022615401146647_j_jaoa.2017.148_ref_051","doi-asserted-by":"publisher","first-page":"e0142222","DOI":"10.1371\/journal.pone.0142222","article-title":"Aspirin compared to low intensity anticoagulation in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis","volume":"10","author":"Vazquez","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2017.148\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2017.148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:40:54Z","timestamp":1645890054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2017.148\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,1]]},"published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["10.7556\/jaoa.2017.148"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2017.148","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}